Leerink Partnrs Reduces Earnings Estimates for Certara

Certara, Inc. (NASDAQ:CERT) – Research analysts at Leerink Partnrs lowered their FY2027 earnings estimates for Certara in a report released on Friday, April 4th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.37 per share for the year, down from their prior estimate of $0.38. The consensus estimate for Certara’s current full-year earnings is $0.28 per share.

Several other equities analysts have also weighed in on CERT. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 target price for the company. Barclays lifted their price target on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Finally, Stephens restated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.83.

Certara Stock Down 3.4 %

CERT opened at $9.05 on Monday. The company has a fifty day moving average of $11.87 and a two-hundred day moving average of $11.37. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -45.25, a PEG ratio of 9.29 and a beta of 1.64. Certara has a fifty-two week low of $8.72 and a fifty-two week high of $19.18. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Institutional Trading of Certara

Several large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Certara by 1.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 699,575 shares of the company’s stock worth $8,192,000 after buying an additional 12,720 shares in the last quarter. State Street Corp grew its stake in Certara by 3.4% during the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after acquiring an additional 122,411 shares in the last quarter. Jane Street Group LLC raised its holdings in Certara by 2.6% in the 3rd quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock valued at $1,726,000 after acquiring an additional 3,732 shares during the last quarter. Barclays PLC lifted its stake in Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after purchasing an additional 46,880 shares in the last quarter. Finally, 272 Capital LP acquired a new position in shares of Certara during the 3rd quarter worth approximately $586,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.